Диссертация (1174213), страница 45
Текст из файла (страница 45)
– Р. 1042–1046.269. Luger S. Prescription frequency and predictors for the use of noveldirect oral anticoagulants for secondary stroke prevention in the first year aftertheir marketing in Europe--a multicentric evaluation /Luger S, Hohmann C, KraftP, Halmer R, Gunreben I, Neumann-Haefelin T, Kleinschnitz C, Walter S,Haripyan V, Steinmetz H, Foerch C, Pfeilschifter W // Int J Stroke. – 2014/ №9(5). – Р.569-75. doi: 10.1111/ijs.12289.270. Mamas MA. A meta-analysis of the prognostic significance of atrialfibrillation in chronic heart failure /Mamas MA, Caldwell JC, Chacko S, GarrattCJ, Fath-Ordoubadi F, Neyses L // Eur J Heart Fail. – 2009. - №11.
– Р.676–683.271. Mancia G. 2013 ESH/ESC Guidelines for the management of arterialhypertension: the Task Force for the management of arterial hypertension of the261European Society of Hypertension (ESH) and of the European Society ofCardiology (ESC) / Mancia G, Fagard R, Narkiewicz K et al.; Task ForceMembers // J Hypertens.
– 2013. - №31(7). – Р.1281–357.272. Manolis AJ. Hypertension and atrial fibrillation: diagnostic approach,prevention and treatment. Position paper of the Working Group ‘HypertensionArrhythmias and Thrombosis’ of the European Society of Hypertension /ManolisAJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K,Parati G, Redon J, Schmieder R, Tsioufis C, Mancia G // J Hypertens. – 2012. №30. – Р.239–252.273. Mant J.
Warfarin versus aspirin for stroke prevention in an elderlycommunity population with atrial fibrillation (the Birmingham Atrial FibrillationTreatment of the Aged Study, BAFTA): a randomised controlled trial /Mant J,Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTAinvestigators; Midland Research Practices Network (MidReC) // Lancet. – 2007. №370(9586). – Р.493-503.274. Marinigh R. Severe renal impairment and stroke prevention inatrialfibrillation: implications for thromboprophylaxis and bleeding risk /MarinighR, Lane DA, Lip GY // JACC.
– 2011. - №57. – Р.1339–1348.275. Maron BJ. Contemporary definitions and classification of thecardiomyopathies: an American Heart Association Scientific Statement from theCouncil on Clinical Cardiology, Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics andTranslational Biology Interdisciplinary Working Groups; and Council onEpidemiology and Prevention /Maron BJ, Towbin JA, Thiene G, et al. //Circulation. – 2006. - №113. – Р.1807–1816.276.
Marott SC. Antihypertensive treatment and risk of atrial fibrillation: anationwide study /Marott SC, Nielsen SF, Benn M, Nordestgaard BG // Eur HeartJ. – 2014. - №35. – Р.1205–1214.277. Martinez C. Therapy persistence in newly diagnosed non-valvular atrialfibrillation treated with warfarin or NOAC. A cohort study /Martinez C, KatholingA, Wallenhorst C, Freedman SB // Thromb Haemost.
– 2016. - №115. – Р.31-39.278. McKinnon M. Hypertension In The Emergency Department: TreatNow, Later, Or Not At All /McKinnon M, O’Neill JM // Emergency MedicinePractice. - 2010. - Vol. 12(6).279. Mendelow AD. Early surgery versus initial conservative treatment inpatients with spontaneous supratentorial intracerebral haematomas in theInternational Surgical Trial in Intracerebral Hemorrhage (STICH): a randomizetrial /Mendelow AD, Gregson BA, Fernandes HM. STICH investigators // Lancet.- 2005. - №365.
- Р. 387-397.280. Meschia JF. Guidelines for the primary prevention of stroke: astatement for healthcare professionals from the American HeartAssociation/American Stroke Association /Meschia JF, Bushnell C, Boden-AlbalaB, Braun LT, Bravata DM, Chaturvedi S, et al; American Heart Association StrokeCouncil; Council on Cardiovascular and Stroke Nursing; Council on Clinical262Cardiology; Council on Functional Genomics and Translational Biology; Councilon Hypertension // Stroke.
– 2014. - №45. – Р.3754–3832. doi:10.1161/STR.0000000000000046.281. Min Li. Systematic review and meta-analysis of chronic kidneydisease as predictor of atrial fibrillation recurrence following catheter ablation/Min Li, Tong Liu, Di Luo, Guangping Li // Cardiol J. – 2014. - №21(1). – Р.8995. DOI: 10.5603/CJ.a2013.0116282. Miyasaka Y. Secular trends in incidence of atrial fibrillation in OlmstedCounty, Minnesota, 1980 to 2000,and implications on the projections for futureprevalence /Miyasaka Y, Barnes ME, Gersh BJ, et al.// Circulation. – 2006.
№114. – Р. 119–125.283. Morgado M. Predictors of uncontrolled hypertension andantihypertensive medication nonadherence /Morgado M, Rolo S, Macedo AF et al.//J Cardiovasc Dis Res. – 2010. - №1(4). – Р. 196–202.284. Morgan CL. Warfarin treatment in patients with atrial fibrillation:Observing outcomes associated with varying levels of INR control /Morgan CL,McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM // Thromb Res. –2009. - № 124 (1).
– Р. 37–41. http://dx.doi.org/10.1016/j.thromres.2008.09.016.285. Morrissey EC. Effectiveness and content analysis of interventions toenhance medication adherence and blood pressure control in hypertension: Asystematic review and meta-analysis /Morrissey EC, Durand H, Nieuwlaat R,Navarro T, Haynes RB, Walsh JC, Molloy GJ // Psychol Health. – 2017.
-№32(10). – Р.1195-1232.286. Motloch LJ. Characteristics of coronary artery disease among patientswith atrial fibrillation compared to patients with sinus rhythm /Motloch LJ, RedaS, Larbig R, Wolff A, Motloch KA, Wernly B, Granitz C, Lichtenauer M, WolnyM, Hoppe UC // Hellenic J Cardiol. – 2017. - Mar 11.doi:10.1016/j.hjc.2017.03.001.287. Mozaffarian D. Heart Disease and Stroke Statistics-2016 Update: AReport From the American Heart Association / Mozaffarian D, Benjamin EJ, GoAS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP,Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, KisselaBM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK,Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW,Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W,Sorlie PD, Stein J, Towfighi A, Turan TN,Virani SS, Woo D, Yeh RW, TurnerMB; American Heart Association Statistics Committee.; Stroke StatisticsSubcommittee // Circulation.
– 2016. - №133(4). – Р. e38-360. doi:10.1161/CIR.0000000000000350.288. Mullen MT. Blood Pressure management in acute and recurrent stroke/Mullen MT, McKinney JS, Kasner SE // Stroke. - 2009. - №40. - Р. 2251-2256.289. Nabauer M. The Registry of the German Competence NETwork onAtrial Fibrillation: patient characteristics and initial management /Nabauer M,Gerth A, Limbourg T, et al. // Europace. – 2009. - №11. – Р.423–434.263290.
Nabauer M. Registry and studies of the German Competence Networkon Atrial Fibrillation (AFNET) /Nabauer M, Gerth A, Kirchhof P, GoetteA, Limbourg T, Sprenger C, Hoffmann B, Willems S, Doll N, Schuchert A, OeffM, Ravens U, Meinertz T, Steinbeck G, Breithardt G // HerzschrittmachertherElektrophysiol. – 2010. - №21(3).
– Р.153-9. doi: 10.1007/s00399-010-0097-7.291. Naccarelli GV. Increasing prevalence of atrial fibrillation and flutter inthe United States /Naccarelli GV, Varker H, Lin J, Schulman KL // Am J Cardiol.– 2009. - №104. – Р.1534–1539.292. Naess H. Persistent atrial fibrillation is associated with worse prognosisthan paroxysmal atrial fibrillation in acute cerebral infarction /Naess H, WajeAndreassen U, Thomassen L // ISRN Cardiol. – 2012. - 650915.
doi:10.5402/2012/650915.293. Nakanishi K. Association of chronic kidney disease with impaired leftatrial reservoir function: A community-based cohort study /Nakanishi K, Jin Z,Russo C, Homma S, Elkind MS, Rundek T, Tugcu A, Sacco RL, Di Tullio MR //Eur J PrevCardiol. – 2017. - № 24(4). – Р.392-398. DOI:10.1177/2047487316679903.294. Neal B. Effects of ACE inhibitors, calcium antagonists, and otherblood-pressure-lowering drugs: results of prospectively designed overviews ofrandomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration/Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists'Collaboration // Lancet. – 2000.
- № 9;356(9246). – Р. 1955-64.295. Nielsen PB. Effectiveness and safety of reduced dose non-vitamin Kantagonist oral anticoagulants and warfarin in patients with atrial fibrillation:propensity weighted nationwide cohort study /Nielsen PB, Skjøth F, Søgaard M,Kjældgaard JN, Lip GY, Larsen TB // BMJ.
– 2017. - № 10;356. – Р. j510. doi:10.1136/bmj.j510.296. Nieuwlaat R. Atrial fibrillation management: a prospective survey inESC member countries: the Euro Heart Survey on Atrial Fibrillation /Nieuwlaat R,Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. // Eur Heart J. –2005. - №26. – Р.2422-2434.297. Nieuwlaat R. Antithrombotic treatment in real-life atrial fibrillationpatients: a report from the Euro Heart Survey on Atrial Fibrillation /Nieuwlaat R,Capucci A, Lip GY, et al.
// Eur Heart J. – 2006. - №27. – Р.3018-3026.298. Nieuwlaat R. Should we abandon the common practice of withholdingoral anticoagulation in paroxysmal atrial fibrillation? /Nieuwlaat R, Dinh T, OlssonSB, Camm AJ, Capucci A, Tieleman RG, et al; Euro Heart Survey Investigators //Eur Heart J. – 2008. - №29. – Р.915–922. DOI:10.1093/eurheartj/ehn101.299. NuciforaG. Prevalence of coronary artery disease assessed bymultislice computed tomography coronary angiography in patients withparoxysmal or persistent atrial fibrillation /NuciforaG, SchuijfJD, TopsLF,vanWerkhoven JM, Kajander S, Jukema JW, Schreur JH, Heijenbrok MW, TrinesSA, Gaemperli O, Turta O, Kaufmann PA, Knuuti J, Schalij MJ, Bax JJ // Circ264Cardiovasc Imaging.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
